Amcor: Packaging Platform and M&A Integration Study

Cost structure and key dependencies. On the cost side, the most important inputs are resins, polymers, films, paper, metals, energy, labor, and plant depreciation; this is therefore not an "asset-light, pure pricing-power" business but one highly sensitive to material costs and manufacturing efficiency. The fiscal 2026 third-quarter disclosure shows that raw-material cost changes clearly "pass through" to revenue: in some segments lower input prices weighed on sales, while in others cost pass-through had limited effect on revenue. This indicates the company has some cost pass-through mechanism, but it also means revenue contains a material-price pass-through component, so revenue growth cannot simply be read as real demand growth.

Is this business simple, transparent, and easy to understand? If the market closed for five years, would I want to hold it? I consider it an understandable business: customers need packaging, Amcor supplies compliant and functional packaging across materials, geographies, and categories, and it earns a relatively stable but not especially thick profit through scale, process, customer relationships, and execution. If the market closed for five years, I would be willing to hold the business itself, provided the entry price is not too aggressive, because this is not a super-company that "compounds growth on autopilot" without outside scrutiny but a mature industrial enterprise that requires you to keep watching cash flow, synergy delivery, and the pace of deleveraging.

Business understandability score: 4/5.

Industry, Competitive Landscape, and Moat

Industry stage and long-term demand. The packaging industry as a whole is closer to a mature industry than a high-growth one, but mature does not mean bad. Smithers projects the global packaging market at roughly 1.2 trillion dollars in 2025, growing at a 3.5% CAGR to 2030; the flexible packaging market was earlier projected by Smithers to grow at about 3.4% annually through 2026. This suggests the industry's long-term demand is steady growth driven by GDP-plus, consumer-goods mix upgrades, and material substitution, not explosive growth.

Could the industry be disrupted? The real risk is not that "packaging suddenly disappears" but the ongoing restructuring at the material, regulatory, and customer-preference level. For example, the EU's Packaging and Packaging Waste Regulation took effect in February 2025 and will apply broadly from August 12, 2026; the FDA also continues to regulate the safety of food-contact materials; and OECD plastics-policy research in recent years has repeatedly stressed source reduction, circular design, and tighter upstream policy. This means packaging will not disappear, but "which materials, structures, recycling solutions, additives, and barrier technologies remain acceptable to customers and regulators" will keep changing. For Amcor this is both a risk and an opportunity for technology upgrades and share consolidation.

Main competitors and industry position. Based on Amcor's own peer set and what is publicly visible, packaging and related comparables include Crown, Sealed Air, Silgan, Graphic Packaging, and Sonoco. After completing the Berry acquisition, Amcor's scale rose markedly, and the company defines itself as a "global leader"; fiscal 2026 third-quarter sales were 5.914 billion dollars for the quarter and 17.108 billion dollars over nine months, showing the combined entity is now clearly larger than most single-name packaging peers.

Is the industry's profit pool concentrated, and does the company have pricing power? This industry is not like luxury goods, where a handful of brand owners capture the overwhelming majority of profit, nor is it like an internet platform with powerful network effects. It resembles a large, fragmented industrial market that is gradually consolidating through M&A and operational optimization. Amcor's pricing power is limited but real: it shows up in customer qualifications, long-term partnerships, materials and structural design capability, global delivery, and cost pass-through, not in an ability to "raise prices a lot whenever I want." In the fiscal 2026 third-quarter disclosure, management repeatedly attributed profit improvement to "synergy gains and cost and productivity improvements, not a combination of higher volume and higher price," which underscores that the core of this business is not exceptional pricing power but operational and scale advantages.

Moat breakdown. Brand advantage: weak, because end consumers buy the brand owner's product, not Amcor's packaging. Cost advantage: moderate, stemming from global procurement, the plant network, materials science, and efficiency gains, but hard to translate into overwhelming excess profit. Scale advantage: moderate to strong; after the Berry merger, 400-plus plants, 40-plus countries, and 77,000 employees make global coverage an important barrier. Network effects: essentially none. Switching costs: moderate, especially in food, medical, and personal-care categories with heavy qualification requirements, where customers do not change packaging suppliers lightly. In the preliminary purchase price allocation from the Berry acquisition, "customer relationships" alone were recorded as roughly 5.5 billion dollars of intangible assets; this is an accounting valuation rather than proof of a moat, but it at least shows customer relationships carry meaningful economic value. Channel advantage: moderate, from the global manufacturing and delivery network. Patents, licenses, and regulatory barriers: moderate to weak, more of a supporting barrier than a core one. Data advantage: weak. Corporate culture and operational capability: moderate to strong; years of cash flow, the capacity network, and synergy progress point to solid execution. Capital allocation capability: only a moderate for now, because the ultimate returns from the Berry acquisition have not yet been validated by time.

Is the moat widening, stable, or narrowing? My judgment: broadly stable, modestly wider in the near term thanks to the Berry acquisition, but also more fragile. It widens through enhanced scale, customer coverage, and R&D capability; it grows more fragile through higher debt, more complex integration, and faster-moving regulation. For a competitor to replicate Amcor's current global platform would take years, billions of dollars of capital, cross-regional customer qualifications, and a great deal of accumulated operating experience; but that does not mean Amcor can earn absurdly high returns on capital. It resembles a "hard-to-replicate excellent industrial system" rather than an "irreplaceable pricing monopolist."

Resilience in inflation and recession. The company can pass through costs to some degree, but transmission usually lags; in a downturn it tends to keep earning profit and cash flow, only with volume growth under pressure. In the fiscal 2026 third quarter, the company estimated combined volume was roughly 1.5% below the prior-year period, yet adjusted EBIT still grew meaningfully, mainly on synergies and cost control; during the COVID-era fiscal 2020, operating cash flow still reached 1.384 billion dollars. This shows that in a recession it behaves more like a "profit-trimmed but not crippled" business.

Industry attractiveness score: 3/5. Moat strength score: 3/5.

Management and Capital Allocation

Is management honest, rational, and long-term oriented? I give a "moderately positive" assessment. One notable plus: in the fiscal 2026 third quarter, the company did not gloss over the situation but explicitly cut its FY2026 free-cash-flow guidance from 1.8–1.9 billion dollars to 1.5–1.6 billion dollars, and directly explained the cause as carrying higher inventory at higher cost to safeguard customer service levels amid the Middle East conflict. Explanations like this do not necessarily please shareholders, but they are more candid than "only talking about adjusted profit while staying silent on inventory and cash tie-up."

Are shareholder interests aligned? Alignment exists, but not strongly enough to be "owner-operator-level concentration." The 2025 proxy shows that as of September 8, 2025, CEO Peter Konieczny held 848,870 shares, and directors and officers held 7.34 million shares in aggregate, each less than 1% of the 2.308 billion shares then outstanding; however, the company also requires the CEO to hold stock worth 500% of base salary and direct reports 300%. This means management is not "without skin in the game," but it is by no means a founder-style large holder.

Capital allocation record. Over the past several years, Amcor's cash use has fallen roughly into four buckets: dividends, modest buybacks, selective small acquisitions, and the enormous Berry acquisition in 2025. On dividends, the company paid 723 million, 722 million, and 845 million dollars in fiscal 2023–2025, with dividends per share rising each year; in the first three quarters of fiscal 2026 it declared quarterly dividends of 0.6375, 0.65, and 0.65 dollars, and in May 2026 the board declared another 0.65 dollar quarterly dividend, implying a yield of about 6.7% at the then-current share price. This reflects management's emphasis on cash returns.

Are buybacks rational? On the whole, Amcor is not an aggressive buyback company. The board approved a 100 million dollar repurchase in 2023, in 2024 merely extended the remaining authorization, and the company did not execute additional repurchases under that program in fiscal 2025; in recent years most buyback cash flow has actually gone toward satisfying equity-award vesting and tax withholding rather than large-scale share reduction when undervalued. This means management has not obviously used buybacks to "flatter EPS," but it also shows it has not made buybacks a powerful capital-allocation tool.

Is the Berry acquisition value-accretive or value-destructive? This is the most critical question, and one not yet fully validated. The fact is that Amcor completed the Berry acquisition on April 30, 2025, for a purchase consideration of about 10.4 billion dollars, and assumed roughly 5.2 billion dollars of Berry debt; management then targeted 650 million dollars of pre-tax synergies by FY2028, of which FY2026 guidance already includes 270 million dollars of pre-tax synergy benefit. The inference is that if most of these 650 million dollars of synergies convert into free cash flow, the deal may ultimately prove accretive; if synergies come slowly, integration costs recur, or customer and plant optimization stumbles, the deal could turn what was a decent defensive company into an asset with "acceptable cash flow but shareholder returns dragged for many years by leverage and amortization." It is still far too early to conclude it has "succeeded."

Equity incentives and dilution. In the first nine months of fiscal 2026, the weighted-average common share count rose from about 288.9 million shares (on a post-reverse-split basis) in the prior-year period to 463.2 million shares; the core driver is not routine equity incentives but the new shares from the Berry acquisition. The company disclosed that it issued about 846 million shares of common stock to Berry shareholders upon completion (on a basis before the subsequent 1-for-5 reverse split). The true "dilution issue" therefore stems mainly from the acquisition, not from management over-issuing stock for compensation.

Management and capital allocation score: 3/5. Dividend discipline and disclosure candor earn credit; the success or failure of capital allocation after the Berry acquisition still needs two to three years of data to prove.

Financial Quality and Cash Flow

The conclusion first: Amcor's cash-flow quality is generally better than the income statement appears, but in 2025–2026 GAAP profit is materially disturbed by deal transaction fees, inventory step-up amortization, acquired-intangible amortization, and integration costs, so reading the static PE alone easily leads to wrong conclusions.

Key financial data table. The table below relies mainly on the GAAP basis in the company's audited annual reports; free cash flow uses a simplified "operating cash flow minus capital expenditure" basis to observe cash conversion quality and does not equal all of the company's non-GAAP definitions. FY2025/FY2024/FY2023 figures come from the FY2025 10-K; FY2022/FY2021/FY2020 figures come from the FY2022 and FY2021 10-Ks.

This table carries three key conclusions. First, operating cash flow is very steady: even through the pandemic, inflation, and the acquisition, it mostly stayed in the 1.26–1.53 billion dollar range from 2020 to 2025. Second, free cash flow is usually close to or above net income, with only FY2023 clearly weak; this is not a long-term pattern of "inflated profit, poor cash." Third, this business does not require exaggerated capital spending: capex has long run at roughly 3%–4% of sales, showing it is a manufacturer but not the kind of ultra-heavy-asset model that burns more cash the more it grows.

Revenue, margins, and growth quality. On a verified basis, Amcor's sales were 12.468 billion dollars in 2020, 12.861 billion dollars in 2021, 13.640 billion dollars in 2024, and 15.009 billion dollars in 2025; over 2020–2025, revenue compounded at roughly mid-single digits. On margins, gross margin rose from 20.3% in 2020 to 21.2% in 2021, fell back to 19.4% in 2022, was 19.9% in 2024, and dropped to 18.9% in 2025; the 2025 operating margin was only 6.7%, below 2024's 8.9%, mainly because FY2025 included 307 million dollars of restructuring/transaction/integration costs and 246 million dollars of acquired-intangible amortization. By the first nine months of fiscal 2026, the adjusted EBIT margin recovered to 11.6%, above the prior-year period's 11.2%, indicating that post-integration "reported profitability" and "real operating capability" are converging again.

Balance sheet and leverage. This is the area that most warrants caution today. At the end of June 2025, total debt was 14.098 billion dollars and net debt 13.271 billion dollars; by March 31, 2026, total debt rose to 15.853 billion dollars and net debt to 14.266 billion dollars. Roughly stitching together a trailing-twelve-month adjusted EBITDA from FY2025 full-year adjusted EBITDA of 2.186 billion dollars, FY2026 nine-month adjusted EBITDA of 2.628 billion dollars, and FY2025 nine-month adjusted EBITDA of 1.397 billion dollars gives about 3.417 billion dollars; on that basis, current net debt to LTM adjusted EBITDA is about 4.2x, still on the high side. The company discloses that it maintains an investment-grade credit rating and complies with its loan covenants, but for a conservative long-term investor this leverage level cannot be taken lightly.

Do accounting profit and cash flow match, and are there signs of fraud or aggressive accounting? I see no obvious signs of financial fraud, but I do see a common post-acquisition issue: a large gap between the GAAP and adjusted bases. For example, FY2025 included 133 million dollars of inventory step-up amortization, 246 million dollars of acquired-intangible amortization, and 307 million dollars of restructuring/transaction/integration costs; the first nine months of fiscal 2026 added 411 million dollars of acquired-intangible amortization and 230 million dollars of restructuring/integration-related costs. These are not necessarily unreal, but they make surface metrics like "PE" and "EPS growth" very hard to compare directly. So watching operating cash flow, actual free cash flow, net debt to EBITDA, and inventory and receivables changes matters far more than watching GAAP EPS.

Does it have enough survivability in a downturn? Historically, the answer is most likely yes. In fiscal 2020, under the pandemic shock, the company still had 1.384 billion dollars of operating cash flow; in the first nine months of fiscal 2026, although free cash flow was pressured by integration and inventory factors, management still maintained full-year free-cash-flow guidance of 1.5–1.6 billion dollars and kept paying dividends. This does not guarantee safety, but it indicates this is not a fragile business model that needs shareholders to inject fresh capital at the first headwind.

Owner Earnings, Valuation, and Margin of Safety

The current market price is as follows.

Start with two valuation bases. Per market data, AMCR currently trades at about 38.38 dollars, with a market cap of about 17.745 billion dollars, a static PE of about 26.1x, against trailing-twelve-month EPS of about 1.47 dollars. But this static PE is severely distorted by acquisition amortization and integration costs; using the FY2026 guidance midpoint of 4.005 dollars in adjusted EPS, the current forward adjusted PE is only about 9.6x. I believe the latter is closer than the former to the economic reality of "how much this business can earn once integration stabilizes."

Conservative Owner Earnings estimate. In the first full year after the acquisition, the most prudent approach is not to extrapolate from FY2025's GAAP net income but to treat the FY2026 company free-cash-flow guidance of 1.5–1.6 billion dollars as a conservative Owner Earnings anchor. The reason is simple: it already incorporates higher inventory and geopolitical disruption, and in the first nine months of fiscal 2026 the company also incurred about 262 million dollars of net transaction, restructuring, and integration cash costs, suggesting real operating cash capability may exceed this "conservative anchor." So I offer two bases: Conservative Owner Earnings: 1.55 billion dollars; Closer-to-normalized Owner Earnings: 1.7–1.8 billion dollars. On the conservative basis, Owner Earnings per share is about 3.35 dollars, putting the current price at about 11.4x Owner Earnings; on the normalized basis, about 10–11x. For a mature, defensive, non-hypergrowth industrial business, this is not expensive, but it is not "mispriced" either.

Method one: Owner Earnings discounting. The table below is based on a conservative model where "Owner Earnings belong to shareholder cash flow"; all figures are my inferences, not company guidance. The discount rate already accounts for leverage, integration, and regulatory risk across scenarios. The input basis comes mainly from the current share price, the company's FY2026 guidance, the current net debt position, and the post-acquisition margin recovery.

My reading: the conservative value is close to the current price, the neutral value is slightly above it, and the optimistic value is clearly above it. This is exactly why I assign "Watch" rather than "Avoid": the current price is no longer expensive, but the margin of safety comes mainly from "whether you believe management can finish the integration," not from "today's price already being absurdly undervalued."

Method two: relative valuation. Looking at static PE directly, AMCR's 26.1x is clearly above most packaging peers: Crown at about 15.4x, Sealed Air at about 11.4x, Silgan at about 14.2x, Graphic Packaging at about 11.1x, while Sonoco's 4.8x is very likely distorted by one-off factors. But once you switch to FY2026 adjusted EPS, AMCR's forward adjusted PE of about 9.5x is instead below most peers. In other words, whether Amcor is "expensive or cheap" depends heavily on whether you measure it by post-acquisition GAAP profit or post-integration adjusted earnings power. For a rigorous investor, I weight cash flow and deleveraging more heavily, so I treat it as "relatively inexpensive, but you cannot call it cheap purely on the adjusted basis."

Look next at the cash-flow basis: on FY2025 simplified free cash flow of 810 million dollars, the current P/FCF is about 21.9x; on the company's disclosed FY2025 adjusted free cash flow of 926 million dollars, about 19.2x; but on the FY2026 guidance of 1.5–1.6 billion dollars, P/FCF falls to about 11.1–11.8x. This again shows that Amcor is not a "statically cheap" stock right now but a stock that would look cheap if synergies land and cash flow recovers, and is merely fair value or slightly expensive if the recovery disappoints.

Method three: asset or liquidation value. This is not Amcor's strong valuation method. At the end of June 2025, total shareholders' equity was 11.740 billion dollars, but goodwill was 11.276 billion dollars and intangible assets 7.403 billion dollars, totaling 18.679 billion dollars, meaning tangible net assets are negative, roughly negative 6.939 billion dollars. Amcor is therefore by no means a classic "buy below book value" candidate; its value comes from ongoing operating cash flow, not liquidation value. For a conservative investor, this matters a great deal: what you are buying is the next ten years of cash-generation capacity, not a safety cushion you could recover today by breaking up and selling assets.

Intrinsic value range and buy/sell levels. Based on the three methods above, I offer the following ranges: Conservative intrinsic value range: 35–40 dollars; Fair intrinsic value range: 42–50 dollars; Optimistic intrinsic value range: 54–60 dollars. At the current 38.38 dollar price, it sits roughly near "the top of the conservative range and the bottom of the fair range." For a conservative value investor, I would want to see at least a 15%–20% discount to conservative value before upgrading it from "Watch" to "Cautious Buy." Therefore: Ideal buy range: 32–35 dollars; Acceptable holding range: 35–44 dollars; Clearly overvalued range: above 50 dollars.

Is the margin of safety sufficient? My answer: not yet sufficient. The most fragile assumption is not "whether consumers still need packaging" but "whether Berry synergies will land at high quality as management envisions and convert into distributable free cash flow." If it can only reach "limited margin recovery, free cash flow hovering around 1.2–1.3 billion dollars, and net debt to EBITDA persistently above 4x," then today's price is hardly cheap. Conversely, if synergies come through and deleveraging advances smoothly over the next two years, today's price will look unremarkable in hindsight. In other words, Amcor right now looks more like a good company at a not-bad price, but not yet a particularly good price.

Risks, Comparisons, Checklist, and Final Conclusion

The most important risks. The core competitive risk is not that a peer suddenly drives it out of the market but industry price competition, customers' internal procurement consolidation, and packaging-structure upgrades that erode the profitability of older products. Technology substitution and regulatory risk are also real: the EU's PPWR will push stricter recyclability and reuse requirements, and the FDA and regulators in various countries will keep tightening safety requirements for food-contact packaging; these changes may require Amcor to step up R&D and retooling spending and make some high-margin legacy products obsolete faster.

Financial leverage risk is equally important. Net debt at the end of March 2026 was 14.266 billion dollars, while my estimated trailing-twelve-month adjusted EBITDA is about 3.417 billion dollars, implying net debt to EBITDA of about 4.2x. This is not yet dangerous enough to threaten the company's survival, but it is enough to make equity returns sensitive to interest rates, credit spreads, integration missteps, and operational softness.

Accounting risk is not a "suspicion of fraud" but that the adjusted basis looks too good and the GAAP basis too ugly. Both FY2025 and the first nine months of fiscal 2026 carry sizable acquired-intangible amortization, inventory step-up amortization, integration costs, and transaction fees. For a long-term investor, the biggest risk is not short-term EPS volatility but being persuaded by "adjusted profit" while overlooking deleveraging, inventory tie-up, and real free cash flow.

The strongest counterargument. The strongest bear case is actually not complicated: this is a mature manufacturer that looks undervalued but is in reality held hostage by M&A integration and high leverage. Stable packaging demand does not guarantee shareholders earn big; if organic volume stays weak for the long run, profit improvement relies mainly on synergies and headcount cuts, regulation forces continual retooling, and dividends lock up large amounts of cash, then shareholders may end up with "high dividends plus low growth plus a chronically mediocre share price." From 2020 to 2025, Amcor's total return rose from 100 to only 112.74, clearly lagging the same-period S&P 500's 215.89 and also trailing its peer group's 126.58; this is a reminder that a stable business does not automatically equal a good stock.

What facts would overturn the investment judgment? If two or three of the following come to pass, I would consider the original judgment to need a clear downgrade: First, net debt to EBITDA is still clearly above 4x at the end of FY2027; Second, synergy delivery falls significantly behind management's roadmap, and adjusted EBIT margin cannot stabilize at 11%-plus; Third, the dividend starts to depend on added leverage rather than free-cash-flow coverage; Fourth, packaging regulation drives persistently rising large capital expenditure without corresponding price and share returns; Fifth, core consumer and medical customer categories see prolonged volume declines without price pass-through. Should any of these occur, Amcor could slide from "steady but ordinary" toward a "high-leverage, low-growth, mediocre-return" value trap.

Comparison with other opportunities. Against purer packaging peers in the industry, Amcor's advantages are scale, dividends, and near-term synergy upside, while its disadvantages are higher integration complexity, dirtier financials, and higher leverage. Against the S&P 500, Amcor's historical shareholder return lags significantly, but its dividend yield is currently higher and its valuation lower; this means it may suit a defensive/income holding rather than a core growth asset. Against the U.S. 10-year Treasury yield of 4.56%, Amcor's current annualized dividend yield is about 6.7%, and on a conservative Owner Earnings estimate about 8%–9%; the risk compensation is not absent, but it is not so generous that I would buy blindly when the margin of safety is insufficient. If you could hold only 5 assets, I do not think it deserves a spot in the core 5 for now; a more fitting role is "defensive watch list, awaiting a better entry point or clearer proof of integration."

Investment Checklist. The judgments below are an integrated conclusion drawn from the facts above and my valuation inferences.

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Amcor is an easy-to-understand, defensive global packaging platform with decent cash flow, but the current price looks more "fairly priced to slightly low" than "clearly undervalued," and success hinges heavily on synergy delivery and deleveraging execution after the Berry acquisition.

【Core Bull Case】

• End demand is dominated by essential or high-frequency consumption such as food, beverage, medical, and personal care, with historically strong operating cash-flow resilience.

• After the Berry acquisition, scale and product coverage improved markedly, with high synergy targets that, if delivered, would lift margins and cash flow.

• The current dividend yield is about 6.7%, and on FY2026 adjusted EPS the forward valuation is about 9.5x, not expensive.

• In the first nine months of fiscal 2026, the adjusted EBIT margin improved to 11.6%, showing integration is already producing positive feedback at the operating level.

【Core Bear Case】

• Net debt is high, with estimated net debt to LTM adjusted EBITDA of about 4.2x, which conservative investors should not dismiss.

• Whether the current valuation is cheap depends heavily on the "adjusted basis," while the FY2025–FY2026 financials are heavily affected by acquisition amortization and integration costs.

• Organic volume is not strong; combined volume in the fiscal 2026 third quarter was about 1.5% lower, and much of the profit improvement came from synergies and cost measures.

• Tangible net assets are negative, providing no typical asset-based safety cushion.

• Historical total return significantly underperformed the S&P 500, showing a "good business" did not automatically translate into a "good stock."

【Key Assumptions】

• FY2026–FY2028 synergies are broadly delivered per the roadmap.

• Free cash flow can hold steady at a level of at least 1.5 billion dollars.

• Net debt to EBITDA can keep declining over the next 2–3 years.

• Packaging regulatory upgrades do not let capital expenditure and material-substitution costs spiral out of control over the long run.

【Fair Buy Price】 32–35 dollars. Rationale: this range provides a more solid margin of safety relative to my conservative intrinsic value of 35–40 dollars, while reserving a discount for integration and leverage risk.

【Target Holding Period】 At least 5–10 years. The investment thesis for this name rests not on next quarter's EPS but on synergy delivery, cash-flow release, deleveraging, and dividend compounding over the coming years.

【Expected Annualized Return】

• Conservative scenario: about 7%–9%, mainly from dividends and modest valuation recovery.

• Neutral scenario: about 10%–12%, assuming cash flow returns near management guidance and the valuation moves back to a fair range.

• Optimistic scenario: about 14%–16%, assuming synergies beat expectations, deleveraging goes smoothly, and the market awards a higher-quality premium.

【Maximum Loss Risk】 For a long-term holder, I believe the worst case could bring a 35%–50% permanent loss of capital. The cause would not be packaging demand disappearing but synergies falling through, leverage failing to come down, regulation and capital expenditure devouring cash, and the dividend being forced to shrink, turning this stock from a "high-dividend defensive name" into a "low-growth, high-leverage value trap."

【Tracking Metrics】 The metrics most worth watching going forward are: operating cash flow; real free cash flow; net debt to EBITDA; adjusted EBIT margin; Berry synergy delivery; inventory days and inventory cost; organic volume growth; capex to sales; dividend coverage; and the share of acquired-intangible amortization and integration costs.

【Signals That Trigger Reassessment】

• Free cash flow clearly below 1.5 billion dollars for two consecutive years.

• Net debt to EBITDA reduction stalls.

• Adjusted profit grows but operating cash flow does not follow.

• Synergy targets are cut or substantially delayed.

• EU/major-market regulatory changes force the company into large-scale product-line restructuring with unclear returns.

【Final Recommendation】 If you are a Buffett-style investor who prizes long-term cash flow and a margin of safety, I would frame Amcor as living in "the lower half of good businesses, on the edge of a good price." It is not the kind of "clearly undervalued quality company" I would buy on impulse, but it is by no means a poor-quality asset to avoid. The more level-headed approach is to keep tracking FY2026 full-year cash-flow delivery, the FY2027 deleveraging pace, and how real the synergies become; if the share price returns to 32–35 dollars, or operating delivery is strong enough to lift conservative intrinsic value meaningfully, then upgrade "Watch" to "Cautious Buy."

Open questions and limitations. The core judgments in this report rely mainly on the company's 10-K, 10-Q, proxy filings, SEC disclosures, and official market data. Because this study prioritized primary sources, I did not fully standardize and rebuild every peer's EV/EBITDA, PB, and ROIC, so the relative-valuation section is better used as a supplement than as a standalone basis for decisions. In addition, some FY2023 balance-sheet line items were not pulled line by line again in this report, so my judgment on long-term ROA/ROIC is more qualitative than a complete time series.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.